Stockreport

FAST III trial demonstrates non-inferiority of CAAS vFFR to invasive wire-based FFR [Yahoo! Finance]

SIEMENS AG SPONS ADR  (SIEGY) 
NASDAQ:AMEX Investor Relations: siemens.com/investor
PDF Reserve) delivers therapeutic outcomes comparable to those achieved with pressure wire–based FFR. Positive non-inferior result validates angiography–based vFFR as a sa [Read more]